# Panacos Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/panacos-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Watertown, US
- Website: www.panacos.com
- Total disclosed funding: $23M
- Latest round: Series C (May 18, 2004)
- Investors on record: 11

## About

Panacos Pharmaceuticals is a biotechnology company focused on developing antiviral therapies. Their research primarily targets innovative treatments for viral diseases, providing solutions for unmet medical needs in the healthcare sector.Panacos Pharmaceuticals, founded in 1999 in Watertown, US, specializes in antiviral drug development. The company underwent a strategic pivot in its operations to enhance its focus on therapeutic solutions. It has successfully raised USD 18.3 mn in its most recent funding round, the Series C, on May 18, 2004, led by notable investors including A. M. Pappas & Associates and Ampersand Capital Partners. The company has completed 2 deals, emphasizing its growth trajectory in the biotechnology landscape.Panacos Pharmaceuticals specializes in developing and commercializing antiviral therapies aimed at addressing significant health challenges. Their flagship product is designed to target viral infections, effectively catering to healthcare providers and research institutions globally. The company serves a diverse clientele, including hospitals and pharmaceutical companies across major markets.The company's revenue model is based on direct sales and partnerships, primarily engaging in B2B agreements for the acquisition of antiviral therapies. Clients typically enter into contractual arrangements, which may involve subscription-based pricing or one-time purchases, facilitating scalable solutions to meet their needs. Revenue generated from these transactions supports Panacos’ growth strategy, allowing for market expansion and enhanced product offerings.Panacos Pharmaceuticals plans to utilize the recent funding of USD 18.3 mn from its Series C round to advance its product development initiatives and expand into new markets. Upcoming therapies designed for viral treatment are in the pipeline, with anticipated launch dates set for the next two years. The company is targeting expansion into emerging markets in Asia and Europe by the end of 2025, aiming to establish a broader presence in the global biotechnology sector.

## Funding rounds

- Series C, May 18, 2004, $18M — Ampersand, Mitsui Global Investment, Maryland Department of Business and Economic Development, William Harris Investors, New England Partners Capital, A. M. Pappas & Associates, Novo Holdings, Lakeview Capital Management
- Series B, Feb 6, 2002, $5M — Ampersand, Pappas Capital, Research Triangle Ventures, Panacos Pharmaceuticals

## Investors

- Ampersand (https://capitalatlas.ai/funds/ampersand) — Series B, Series C
- Pappas Capital (https://capitalatlas.ai/funds/pappas-capital) — Series B
- Research Triangle Ventures (https://capitalatlas.ai/funds/research-triangle-ventures) — Series B
- Panacos Pharmaceuticals — Series B
- Mitsui Global Investment (https://capitalatlas.ai/funds/mitsui-global-investment) — Series C
- Maryland Department of Business and Economic Development — Series C
- William Harris Investors — Series C
- New England Partners Capital — Series C
- A. M. Pappas & Associates — Series C
- Novo Holdings — Series C
- Lakeview Capital Management — Series C